EcoDrugPlus

Methionyl Aminopeptidase 2

Ensembl ID : ENSSLUG00000007275
Gene Symbol: METAP2
3 Cross references
220 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSSLUG00000016463
Gene Symbol: MAPK1
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSSLUG00000003484
Gene Symbol: LOC116065226
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSSLUG00000011456
Gene Symbol: LOC116063029
3 Cross references
88 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSSLUG00000013555
Gene Symbol: LOC116054782
3 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSSLUG00000015633
Gene Symbol: MAPK14
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSSLUG00000007361
Gene Symbol: MAPK14
3 Cross references
206 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSSLUG00000005358
Gene Symbol: LOC116053441
3 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 8b

Ensembl ID : ENSSLUG00000025733
Gene Symbol: MAPK8B
1 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSSLUG00000009242
Gene Symbol: MAPK9
3 Cross references
210 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSSLUG00000000165
Gene Symbol: MAP2K1
3 Cross references
214 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSSLUG00000012846
Gene Symbol: MAP2K2
3 Cross references
212 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).